Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For ag

Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likely acquirers and timing signals.

price-ascending: candidates are ordered by the listed price of the operation, with no managed-first preference applied. Unlike /v1/apis, this surface does not rank Apiosk-settled listings above federated ones — a comparison that reorders on commercial grounds is not a comparison. Pass sort=managed_first for the catalog's ordering.

Compared: listed price, settlement rail and input compatibility. Not measured yet: latency, reliability, result quality, and provider terms such as rate limits, jurisdiction and licensing.